ClinicalTrials.gg
RecruitingNCT07541469Updated Apr 21, 2026

Rezdiffra Pregnancy and Lactation Registry

An observational study in MASH - Metabolic Dysfunction-Associated Steatohepatitis, sponsored by Madrigal Pharmaceuticals, Inc.. Recruiting at 1 site in United States. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Madrigal Pharmaceuticals, Inc. · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
10
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 212 studies in Fatty Liver with a site in United States — 42 open to participants now, 48 under way, 8 of them phase 3. Fatty Liver · United States.

Planned enrollment
43rd of 48
10 · median 85
Started
2026
with 14 others
Observational
48 of 212
10 open now
Primary completion
2030-04
later than 42 of 47 live
Registered
200th of 212
by date

Among the 212 studies in Fatty Liver with a site in United States, this one is the 43rd largest by planned enrollment of the 48 observational ones that give a count, is one of 15 that started in 2026, is one of 48 observational ones, reaches primary completion later than 42 of the 47 other live ones, and was the 200th registered.

Fatty Liver

666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

42 of the 212 studies in Fatty Liver with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 42 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 118 Fatty Liver studies recruiting now, 36 (31%) set no upper age limit and 63 (53%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 212 studies in Fatty Liver with a site in United States, or all of them as a file.
02

Study summary

To evaluate pregnancy and clinical outcomes in women with NASH and their infants after exposure to Rezdiffra at any time during pregnancy and/or lactation.

Read the detailed description

The purpose of the Rezdiffra™ Pregnancy and Lactation Registry is to create a worldwide information source, called a pregnancy registry. The registry will collect information about the safety of Rezdiffra™ (resmetirom), an approved medication, during pregnancy and/or while breastfeeding. This will help doctors and other healthcare providers learn more about its effect on pregnant and breastfeeding women and their infant after delivery up to 12 months of age.

03

Conditions studied

  • MASH - Metabolic Dysfunction-Associated Steatohepatitis

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The registry will allow healthcare providers (HCPs) to enroll eligible patients and will also allow eligible patients to self-enroll. The registry is voluntary.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patients with NASH who have been exposed to at least 1 dose of resmetirom at any time during pregnancy (defined as having received resmetirom within 3 days prior to the date of conception and/or during pregnancy) and/or during lactation, and their infants (up to 12 months of age).
  2. Patient or parent/legally authorized representative must be able to understand and provide consent through an Institutional Review Board/Independent Ethics Committee (IRB/IEC)-approved or assent form.

Exclusion criteria

Exclusion Criteria:

NONE

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
10 participants (estimated)
Target follow-up
21 Months
Patient registry
Yes

Interventions

06

What researchers measure

Primary outcomes

  1. Pregnancy and Infant Outcomes Among Women Exposed to Rezdiffra During Pregnancy and/or Lactation

    To evaluate pregnancy and infant outcomes among women with NASH exposed to Rezdiffra during pregnancy and/or lactation, including pregnancy outcomes, congenital malformations, and infant growth, development, and safety outcomes.

    Time frame: From enrollment through pregnancy and up to 12 months of infant age (participant observational period up to approximately 21 months)

07

Study locations

1 of 1 sites recruiting
  • Madrigal Pharmaceuticals
    West Conshohocken, Pennsylvania 19428, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Apr 2030, 49 months after the start.

Of 97 observational studies under Fatty Liver, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 68. This study's planned 49 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2026
First posted
Apr 21, 2026
StartActual
Mar 4, 2026
Primary completionEst.
Apr 8, 2030
CompletionEst.
Apr 8, 2030
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07541469
Responsible party
Sponsor
First posted
Apr 21, 2026
Start date
Mar 4, 2026
Primary completion
Apr 8, 2030 (estimated)
Completion
Apr 8, 2030 (estimated)
Last update
Apr 21, 2026

Study contacts

Madrigal Pharmaceuticals
Contact
MHGSafety@iconplc.com
800-905-0324

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion